Company OverviewBright Minds Biosciences
Bright Minds (FRA:BMB) is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
Speaker BioCEO
Bright Minds
Mr. McDonald is an entrepreneur and former Investment Banker. Prior to BMB, he served on the management team at a TSX-listed gold mining company. In that capacity, McDonald developed and implemented the corporate strategy as it relates to M&A and capital markets resulting in a $160 million sale within one year.
Speaker BioVice President of Discovery & Co-Founder
Bright Minds
Dr Gideon Shapiro, trained as an organic chemist at University of North Carolina, University of California Berkeley and the Federal Institute of Technology (ETH) is a seasoned drug hunter. His 30+ year professional career is lined with a record of achievement in drug discovery, development and drug program management.
